Iovance Biotherapeutics, Inc. (IOVA)

NGM – Real vaqt narxi. Valyuta: USD

3.56

-0.14 (-3.78%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

08.05.2026

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. markets Amtagvi, a TIL therapy for advanced melanoma, and just reported Q1 earnings. Following Q1 results, IOVA shares declined over 13%, closing at $3.55, with a market cap of $1.59bn. The earnings announcement triggered a notable sell-off, reflecting investor concerns about near-term performance.

07.05.2026

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

07.05.2026

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.

07.05.2026

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates.

30.04.2026

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

28.04.2026

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising efficacy in NSCLC, with a strong clinical pipeline and upcoming catalysts. Commercial ramp of lifileucel is underway, with 2025 sales at $220M and gross margins improving to 50%, but operational and adoption hurdles persist.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
IOVA	UBS	Neutral	undefined >> $2	May 16th 2025
IOVA	Truist	Hold	undefined >> undefined	May 12th 2025
IOVA	Citizens JMP	Market Perform	undefined >> undefined	May 9th 2025

Press-relizlar

07.05.2026

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

17.04.2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 135,470 shares of Iovance's common stock to twelve new, non-executive employees.

20.03.2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance's common stock to one new, non-executive employee.

24.02.2026

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy.

Iovance Biotherapeutics, Inc. (IOVA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Iovance Biotherapeutics, Inc. (IOVA)

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Search stocks

Iovance Biotherapeutics, Inc. (IOVA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Iovance Biotherapeutics, Inc. (IOVA)

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas